ALZN

Alzamend Neuro, Inc. NASDAQ Listed Jun 15, 2021

Healthcare ·Biotechnology ·US · alzamend.com

$1.06

Mkt Cap $3.3M

52w Low $0.84 3.0% of range 52w High $8.22

50d MA $1.45 200d MA $2.08

P/E (TTM) -0.1x

EV/EBITDA 0.4x

P/B 0.1x

Debt/Equity 0.0x

ROE -259.8%

P/FCF -0.3x

RSI (14) —

ATR (14) —

Beta -0.05

50d MA $1.45

200d MA $2.08

Avg Volume 140.5K

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

SIC Code

2834

CIK (SEC)

1677077

Phone

844 722 6333

3500 Lenox Road NE · Atlanta, GA 30326 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 11, 2026	AMC	-0.53	-0.58	-9.4%	2.18	-1.4%	-4.1%	-2.4%	+2.9%	-11.4%	+3.2%	—
Dec 9, 2025	AMC	-0.83	-0.30	+63.9%	2.17	+0.0%	-0.5%	+0.9%	-0.5%	-2.8%	+2.4%	—
Sep 10, 2025	AMC	-3.69	-1.28	+65.3%	2.35	-2.1%	+2.1%	+0.4%	-2.5%	+11.5%	-4.6%	—
Mar 10, 2025	AMC	-2.61	-1.71	+34.5%	6.38	+0.9%	-1.6%	-4.0%	+3.0%	-1.9%	+32.2%	—
Dec 11, 2024	AMC	-21.42	-3.60	+83.2%	10.80	-1.7%	-0.8%	+0.0%	+2.5%	+5.7%	-4.7%	—
Sep 11, 2024	AMC	-2.38	-11.25	-372.7%	18.27	+0.5%	-0.5%	-4.5%	-5.7%	-7.7%	+3.0%	—
Jul 30, 2024	AMC	-2.75	-13.35	-385.5%	30.60	+10.6%	+5.0%	-1.4%	-7.4%	-22.1%	-9.8%	—
Mar 25, 2024	AMC	-0.32	-34.20	-9999.0%	90.90	+4.0%	-1.5%	+2.5%	-2.0%	-12.0%	+3.3%	—
Dec 15, 2023	AMC	-0.67	39.60	+6010.4%	90.00	+2.0%	+0.0%	-4.0%	-12.3%	+6.9%	+0.2%	—
Sep 13, 2023	AMC	-47.23	-53.98	-14.3%	306.45	+1.3%	-1.3%	+7.1%	-6.0%	+6.1%	-3.9%	—
Jul 27, 2023	AMC	-30.36	-40.48	-33.3%	634.32	-6.4%	+0.8%	-4.3%	+3.5%	-2.1%	-14.2%	—
Mar 15, 2023	AMC	-0.04	-0.06	-50.0%	647.19	+4.3%	-4.8%	-12.4%	-7.5%	+13.5%	+4.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Dec 22	Ascendiant Capital	Maintains	Buy → Buy	—	$2.11	$2.10	-0.5%	-0.5%	-1.4%	-1.0%	-1.5%	-3.5%
Sep 25	Ascendiant Capital	Maintains	Buy → Buy	—	$2.38	$2.35	-1.3%	-0.8%	+2.1%	-2.1%	+0.8%	+2.9%
Aug 21	Ascendiant Capital	Maintains	Buy → Buy	—	$2.26	$2.26	+0.0%	+4.0%	+6.0%	-2.8%	+0.8%	+0.8%
Mar 17	Ascendiant Capital	Maintains	Buy → Buy	—	$6.09	$6.41	+5.3%	+32.2%	+5.1%	+1.2%	+2.8%	+3.3%
Dec 16	Ascendiant Capital	Maintains	Buy → Buy	—	$10.71	$10.71	+0.0%	+2.5%	+5.7%	-4.7%	+1.6%	-11.2%
Nov 11	Ascendiant Capital	Maintains	Buy → Buy	—	$13.41	$13.50	+0.7%	+0.7%	+2.0%	-5.2%	+0.7%	-6.8%
Apr 12	Maxim Group	Maintains	Buy → Buy	—	$695.61	$695.25	-0.1%	+10.6%	+1.8%	+1.3%	+0.5%	-5.0%
Oct 1	Ascendiant Capital	Maintains	Buy → Buy	—	$4158.00	$3928.50	-5.5%	-6.5%	+2.4%	-10.5%	-0.8%	+1.1%

Data updated apr 24, 2026 5:38pm · Source: massive.com